STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

XWELL Reports Third Quarter 2025 Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags

XWELL (Nasdaq: XWEL) reported third quarter 2025 results for the period ended September 30, 2025: Revenue $7.3M, Operating loss $0.8M, and Net loss $0.7M. As of September 30, 2025 the company held $4.0M cash, $237,000 in marketable securities, total current assets of $10.8M, and reported no long-term debt.

Recent operational moves include a global expansion of its Priority Pass partnership to the Middle East and Europe, new off-airport wellness centers in Florida and a Penn Station site opening in mid-November, integration of HyperPointe into existing operations, and post-quarter actions reducing approximately $2.4M in annualized staffing costs. XWELL also secured a three-year extension of its traveler genomic surveillance program with CDC and Ginkgo Bioworks.

XWELL (Nasdaq: XWEL) ha riportato i risultati del terzo trimestre 2025 per il periodo terminato il 30 settembre 2025: Ricavi 7,3 milioni di dollari, perdita operativa 0,8 milioni di dollari e perdita netta 0,7 milioni di dollari. Al 30 settembre 2025 la società possedeva contanti per 4,0 milioni di dollari, 237.000 dollari in titoli negoziabili, attività correnti totali di 10,8 milioni di dollari e non ha riportato nessun debito a lungo termine.

Recenti mosse operative includono un'espansione globale della partnership Priority Pass verso Medio Oriente ed Europa, nuovi centri benessere fuori dall'aeroporto in Florida e l'apertura di una sede Penn Station a metà novembre, l'integrazione di HyperPointe nelle operazioni esistenti e azioni post- trimestre che riducono circa 2,4 milioni di dollari i costi del personale annualizzati. XWELL ha inoltre assicurato una estensione di tre anni del suo programma di sorveglianza genomica dei viaggiatori con il CDC e Ginkgo Bioworks.

XWELL (Nasdaq: XWEL) informó resultados del tercer trimestre de 2025 para el periodo terminado el 30 de septiembre de 2025: Ingresos 7,3 millones de dólares, pérdida operativa 0,8 millones de dólares y pérdida neta 0,7 millones de dólares. Al 30 de septiembre de 2025 la empresa tenía 4,0 millones de dólares en efectivo, 237.000 dólares en valores negociables, activos corrientes totales de 10,8 millones de dólares y reportó sin deuda a largo plazo.

Las recientes medidas operativas incluyen una expansión global de su asociación Priority Pass hacia Medio Oriente y Europa, nuevos centros de bienestar fuera del aeropuerto en Florida y la apertura de una sede en Penn Station a mediados de noviembre, la integración de HyperPointe en las operaciones existentes y acciones posteriores al trimestre que reducen aproximadamente 2,4 millones de dólares en costos de personal anualizados. XWELL también aseguró una extensión de tres años de su programa de vigilancia genómica de viajeros con el CDC y Ginkgo Bioworks.

XWELL(나스닥: XWEL)는 2025년 9월 30일 종료된 기간의 2025년 3분기 실적을 발표했습니다: 매출 730만 달러, 영업손실 80만 달러, 및 순손실 70만 달러. 2025년 9월 30일 기준으로 회사는 400만 달러 현금, 237,000달러의 유가증권, 총 1080만 달러의 유동자산을 보유했고 장기 부채 없음을 보고했습니다.

최근 운영 조치로는 Priority Pass 파트너십의 중동 및 유럽으로의 글로벌 확장, 플로리다의 공항 외 웰니스 센터 신규 개설 및 Penn Station 지점의 11월 중순 오픈, 기존 운영에 HyperPointe의 통합 및 분기 이후 약 240만 달러의 연간 인건비 절감 조치가 포함됩니다. XWELL은 또한 CDC 및 Ginkgo Bioworks와의 여행자 게놈 감시 프로그램의 3년 연장도 확보했습니다.

XWELL (Nasdaq : XWEL) a publié les résultats du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025 : Chiffre d'affaires 7,3 millions de dollars, perte opérationnelle 0,8 million et perte nette 0,7 million. Au 30 septembre 2025, la société détenait 4,0 millions de dollars en liquidités, 237 000 dollars en titres négociables, des actifs courants totaux de 10,8 millions de dollars et n'a déclaré aucune dette à long terme.

Les récentes mesures opérationnelles comprennent une expansion mondiale de son partenariat Priority Pass vers le Moyen-Orient et l'Europe, de nouveaux centres de bien-être hors aéroport en Floride et l'ouverture d'un site Penn Station à la mi-novembre, l'intégration de HyperPointe aux opérations existantes et des actions après le trimestre réduisant d'environ 2,4 millions de dollars les coûts de personnel annualisés. XWELL a également obtenu une extension de trois ans de son programme de surveillance génomique des voyageurs avec le CDC et Ginkgo Bioworks.

XWELL (Nasdaq: XWEL) meldete die Ergebnisse des dritten Quartals 2025 für den Zeitraum zum 30. September 2025: Umsatz 7,3 Mio. USD, operativer Verlust 0,8 Mio. USD und Nettoloss 0,7 Mio. USD. Zum 30. September 2025 verfügte das Unternehmen über 4,0 Mio. USD liquide Mittel, 237.000 USD in handelbaren Wertpapieren, insgesamt 10,8 Mio. USD an kurzfristigen Vermögenswerten und meldete keine langfristigen Schulden.

Zu den jüngsten operativen Maßnahmen gehören eine globale Erweiterung der Priority Pass-Partnerschaft in den Nahen Osten und Europa, neue Wellness-Zentren außerhalb des Flughafens in Florida und die Eröffnung eines Penn Station-Standorts Mitte November, die Integration von HyperPointe in den bestehenden Betrieb sowie Maßnahmen nach dem Quartal, die die jährlichen Personal costs um ca. 2,4 Mio. USD senken. XWELL hat außerdem eine dreijährige Verlängerung seines Programms zur genomischen Überwachung von Reisenden mit dem CDC und Ginkgo Bioworks gesichert.

XWELL (ناسداك: XWEL) أبلغت عن نتائج الربع الثالث لعام 2025 للفترة المنتهية في 30 سبتمبر 2025: الإيرادات 7.3 مليون دولار، خسارة تشغيلية 0.8 مليون دولار، وخسارة صافية 0.7 مليون دولار. حتى 30 سبتمبر 2025، تمتلك الشركة 4.0 ملايين دولار نقداً، 237,000 دولار في أوراق مالية قابلة للتداول، إجمالي أصول جارية قدره 10.8 ملايين دولار، ولم تذكر ديون طويلة الأجل.

تشمل التحركات التشغيلية الأخيرة توسيعاً عالمياً لشراكة Priority Pass إلى الشرق الأوسط وأوروبا، ومراكز عافية خارج المطارات جديدة في فلوريدا وافتتاح موقع في Penn Station في منتصف نوفمبر، ودمج HyperPointe ضمن العمليات القائمة، وإجراءات بعد الربع تقلل نحو 2.4 مليون دولار من تكاليف التوظيف السنوية. كما أمنت XWELL تمديداً لمدة ثلاث سنوات لبرنامج رصد الجينوم للمسافرين مع CDC وGinkgo Bioworks.

Positive
  • Revenue $7.3M for Q3 2025
  • Implemented $2.4M annualized staffing cost reduction
  • 3-year TGS extension with CDC and Ginkgo Bioworks (March 2025)
  • Priority Pass partnership expanded to Middle East and Europe
Negative
  • $4.0M cash and limited liquidity as of September 30, 2025
  • Operating loss $0.8M for Q3 2025
  • Total cost of sales $5.9M for Q3 2025 (high relative to revenue)

Insights

XWELL shows clear operational improvement: revenue of $7.3 million, sharply lower losses, and targeted cost reductions that improve near-term runway.

XWELL generated $7.3 million in revenue for the third quarter ended September 30, 2025, with business-line splits of $5.1 million XpresSpa, $1.7 million XpresCheck, and $0.5 million Naples Wax Center. Total cost of sales fell to approximately $5.9 million from $6.4 million year-over-year and total operating expenses declined to approximately $2.3 million (including one-time credits) from $6.8 million, producing an operating loss of about $0.8 million versus $4.8 million in the prior-year quarter. The company reported cash and cash equivalents of approximately $4.0 million, marketable securities of $237,000, total current assets of $10.8 million, and no long-term debt.

The company executed concrete actions to reduce costs and extend distribution. Management removed approximately $2.4 million in annualized staffing costs and integrated the HyperPointe™ business into existing operations to capture further savings while maintaining its digital and AI capabilities. It also expanded the Priority Pass partnership into key international airports in the Middle East and Europe, opened off-airport locations in Florida and plans a Penn Station launch expected in mid-November, which diversify revenue channels beyond airports.

Key dependencies and near-term items to monitor include the realized run-rate impact of the announced $2.4 million staffing reductions, the actual contribution from new off-airport locations and expanded Priority Pass access, and cash burn trends against the reported $4.0 million in cash. Watch quarterly operating loss and cash flow over the next two quarters to confirm the improvement sustains and whether XpresCheck contract activity tied to the three-year TGS extension supports recurring revenue.

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced results for the third quarter ended September 30, 2025.

Recent Operating Highlights

  • Revenue for the 2025 third quarter totaled $7.3 million.
  • Cost of sales decreased approximately 8% from the 2024 third quarter.
  • General and administrative expenses, excluding one-time credits, decreased approximately 32% from the 2024 third quarter.
  • The Company’s Priority Pass partnership has been expanded to key international airports across the Middle East and Europe, providing travelers with broader access to XWELL’s wellness offerings.
  • The Company continues its plans to grow beyond the airport with the opening of new brick-and-mortar locations at Bloomingdale Square in Brandon, Florida, and Waterford Lakes Town Center in Orlando, Florida.
  • In New York City, XWELL’s Penn Station location is set to open in mid-November, offering a convenient grab-and-go destination with wellness essentials designed to meet the needs of busy commuters.
  • Subsequent to the end of the third quarter XWELL streamlined its cost structure, reducing approximately $2.4 million in annualized staffing costs.

“We believe we are making meaningful progress against our priorities from diversifying access points, elevating brand relevance, and engaging with consumers wherever wellness matters the most,” said Ezra Ernst, CEO of XWELL. “Our expanded partnership with Priority Pass builds on the tremendous response we’ve seen from travelers across our U.S. airport spas, while the openings of off-airport wellness centers in Penn Station and several Florida markets demonstrate how XWELL is successfully extending its services to customers where they live, work, and travel. Supported by our long-standing CDC partnership, ongoing operational discipline and targeted growth strategy, I am confident in the opportunities that lie ahead for XWELL.”

Reduced Corporate Infrastructure
XWELL also announced today that subsequent to the end of the 2025 third quarter, it implemented targeted actions to streamline its corporate cost structure, including removing approximately $2.4 million in annualized staffing costs. Additionally, as part of this initiative to optimize resources and align operations around its most critical business priorities, the Company integrated its HyperPointe™ business into existing operations. This action is anticipated to deliver meaningful cost savings while maintaining XWELL’s digital platform and AI capabilities, which are critical for supporting future growth.

“Following the end of the third quarter, we took decisive steps to streamline our cost structure and align operations around our most critical growth priorities,” Ezra Ernst added. “While decisions like these are never easy, with our operational foundation and infrastructure now in order, we believe XWELL remains well-positioned to expand efficiently both inside and outside of airports.”

Momentum Building Across Wellness Channels and Brands
During the past several months, XWELL has achieved various milestones that demonstrate the Company’s momentum in expanding beyond airport terminals and into broader consumer wellness markets. Its new off-airport locations feature a curated selection of health, wellness, and beauty treatments, each delivering the cohesive, elevated, and expert-led XWELL experience to an even wider audience. Recent highlights include:

  • In October 2025, the Company announced the global expansion of its partnership with Priority Pass, the world’s leading airport experiences program. Originally launched in North America, the partnership has now extended to key international airports across the Middle East and Europe, providing travelers with broader access to XWELL’s wellness offerings.
  • Building on the Company’s strong foundation in Orlando, Florida -- where XWELL has long served wellness-minded travelers at its XpresSpa in Orlando International Airport -- XWELL opened a new wellness center at Waterford Lakes in early September 2025. To celebrate the occasion, XWELL was joined by the Orlando Magic which created an exciting, community-driven grand opening experience that brought together wellness enthusiasts, families and fans from across the region. As previously announced, XWELL was named the official wellness spa of the Orlando Magic through a multiyear partnership.
  • Representing another important step in its brick-and-mortar off-airport growth strategy, in mid-September 2025 XWELL strengthened its presence in Florida with the grand opening of a wellness center at Bloomingdale Square in Brandon, Florida.
  • In New York City, New York the Company’s new Penn Station location is currently set to open in mid-November and is expected to serve as a convenient grab-and-go destination offering wellness essentials tailored to busy commuters.   Strategically positioned in one of the nation’s busiest transportation hubs, this tech-forward location is expected to focus on serving commuters, neighborhood locals and tourists with wellness-focused retail, autonomous massage, and nail care services, enabling seamless and efficient experiences.
  • XWELL also continues to pursue opportunities to potentially acquire complementary businesses and extend its reach into the broader wellness consumer landscape.

Biosecurity Program
Through XpresCheck, XWELL operates at the forefront of global biosecurity.

In March 2025, XWELL secured a three-year extension of its Traveler-based Genomic Surveillance Program (“TGS”), operated with the CDC and Ginkgo Bioworks Holdings. The TGS program, provides early detection of emerging pathogens, safeguarding national health through airport-based biosurveillance.

Building on this foundation, XWELL’s biosecurity platform and expertise position the Company to capture new international growth opportunities across travel and mass-gathering settings. This includes biosecurity at large-scale deployments at high-profile global events such as the 2026 World Cup, the Haj, the 2026 Winter Olympics in Italy and the 2028 Summer Olympics in Los Angeles.

XpresCheck, which helped power national COVID-19 testing and reporting during the pandemic, now serves as the operational and technological core of this next phase of XWELL’s strategic, science-driven wellness initiatives.

Liquidity and Financial Condition
As of September 30, 2025, the Company had approximately $4.0 million of cash and cash equivalents (excluding restricted cash), approximately $237,000 in marketable securities, total current assets of approximately $10.8 million, and no long-term debt.

Third Quarter Financial Overview

  • Revenue: Approximately $7.3 million for the three months ended September 30, 2025, consisted of approximately $5.1 million for XpresSpa, approximately $1.7 million for XpresCheck, and approximately $0.5 million for Naples Wax Center.
  • Total Cost of Sales: Approximately $5.9 million for the three months ended September 30, 2025, compared with approximately $6.4 million in the comparable prior year period.
  • Total Operating Expenses: Approximately $2.3 million, including one-time credits, for the three months ended September 30, 2025, compared with approximately $6.8 million in the comparable prior year period.
  • Operating Loss: Approximately $0.8 million for the three months ended September 30, 2025, compared with approximately $4.8 million in the comparable prior year period.
  • Net Loss Attributable to XWELL: Approximately $0.7 million for the three months ended September 30, 2025, compared with approximately $4.8 million in the comparable prior year period.

About XWELL, Inc. 
XWELL, Inc. (Nasdaq: XWEL) is a global wellness company on a mission to liberate science-proven wellness for all. Through a portfolio of brands that include XpresSpa®, Naples Wax Center®, and XpresCheck®, XWELL delivers accessible, real-world wellness across travel, retail, and clinical settings. For more information on XWELL’s offerings, visit www.XWELL.com.

Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Forward-looking statements relating to expectations about future results or events are based upon information available to XWELL as of the date of this press release, and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company’s Annual Report on Form 10-K, as amended, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XWELL, or other matters and attributable to XWELL or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XWELL does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof. 

Media Contact:
Heather Tidwell
MWW
htidwell@mww.com


FAQ

What were XWELL (XWEL) Q3 2025 revenue and net loss numbers?

XWELL reported Q3 2025 revenue $7.3M and a net loss $0.7M for the quarter ended September 30, 2025.

How much cash did XWELL (XWEL) have on September 30, 2025?

As of September 30, 2025 XWELL had approximately $4.0M cash and $237,000 in marketable securities.

What cost reductions did XWELL (XWEL) announce after Q3 2025?

Subsequent to Q3 2025 XWELL reduced approximately $2.4M in annualized staffing costs and integrated HyperPointe into existing operations.

What is the scope of XWELL's Priority Pass expansion mentioned in the Q3 2025 report?

XWELL expanded its Priority Pass partnership from North America to key international airports across the Middle East and Europe.

Did XWELL (XWEL) secure any public-health or biosecurity contracts in 2025?

Yes; in March 2025 XWELL secured a three-year extension of its traveler-based Genomic Surveillance Program with CDC and Ginkgo Bioworks.
XWELL Inc

NASDAQ:XWEL

XWEL Rankings

XWEL Latest News

XWEL Latest SEC Filings

XWEL Stock Data

4.78M
4.74M
17.68%
14%
1.47%
Diagnostics & Research
Services-personal Services
Link
United States
NEW YORK